Rise Therapeutics enrols first patient in trial of type 1 diabetes drug R-5280
The trial aims to assess the immunotherapeutic medicine’s safety in treating patients with new onset T1D.
16 July 2024
16 July 2024
The trial aims to assess the immunotherapeutic medicine’s safety in treating patients with new onset T1D.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.